机构

• 合肥物质科学研究院 [4]
• 上海药物研究所 [2]
• 大连化学物理研究所 [2]
• 昆明植物研究所 [1]

采集方式

• OAI收割 [9]

内容类型

• 期刊论文 [9]

发表日期

• 2019 [1]
• 2017 [2]
• 2014 [1]
• 2011 [3]
• 2009 [1]
• 2008 [1]
• 更多

学科主题

• Oncology [2]
• Pharmacolo... [2]

筛选

浏览/检索结果: 共9条，第1-9条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择题名升序题名降序提交时间升序提交时间降序作者升序作者降序发表日期升序发表日期降序 Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines 期刊论文  OAI收割 ONCOLOGY LETTERS, 2019, 卷号: 18, 期号: 3, 页码: 2977-2984 作者:  Wang, Hui-Li;  Liu, Yan-Chun;  Long, Ming-Peng;  Zheng, Chuan;  Yang, Jia-Hui   |  收藏  |  浏览/下载：107/0  |  提交时间：2019/11/07 receptor tyrosine kinase-like orphan receptor 1  lung adenocarcinoma  erlotinib resistance  AKT  mammalian target of rapamycin  small interfering RNA   Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1 期刊论文  OAI收割 ACTA PHARMACEUTICA SINICA B, 2017, 卷号: 7, 期号: 6, 页码: 657-664 作者:  Cheng, Xuewei;  Lv, Xia;  Qu, Hengyan;  Li, Dandan;  Hu, Mengmeng   |  收藏  |  浏览/下载：37/0  |  提交时间：2019/06/20 Icotinib  Erlotinib  Ugt1a1  Inhibitory Effects  Drug-drug Interacts (Ddis)   Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations 期刊论文  OAI收割 CHINESE JOURNAL OF CANCER RESEARCH, 2017, 卷号: 29 -   |  收藏  |  浏览/下载：15/0  |  提交时间：2020/10/26 EGFR MUTATIONS  GEFITINIB TREATMENT  1ST-LINE TREATMENT  OPEN-LABEL  RARE  MULTICENTER  ERLOTINIB  GENE  CHEMOTHERAPY  EFFICACY  Non-small cell lung cancer  EGFR  uncommon mutation  target therapy   Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy 期刊论文  OAI收割 CHINESE MEDICAL JOURNAL, 2014, 卷号: 127 -   |  收藏  |  浏览/下载：16/0  |  提交时间：2020/10/26 PREVIOUSLY TREATED PATIENTS  TYROSINE KINASE INHIBITORS  FACTOR RECEPTOR MUTATIONS  SKIN RASH  ERLOTINIB EFFICACY  GEFITINIB  EGFR  TRIAL  BENEFIT  ADENOCARCINOMA  non-small cell lung cancer  icotinib  antitumor activity  adverse events   Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib 期刊论文  OAI收割 acta pharmacologica sinica, 2011, 卷号: 32, 期号: 3, 页码: 399-407 作者:  Dong, Pei-pei;  Fang, Zhong-ze;  Zhang, Yan-yan;  Ge, Guang-bo;  Mao, Yu-xi 收藏  |  浏览/下载：32/0  |  提交时间：2015/11/12 erlotinib  CYP isoform  human liver microsomes  substrate-dependent inhibition (or modulation)  drug interaction   Detecting the epidermal growth factor receptors status in non-small cell lung cancer 期刊论文  OAI收割 CHINESE MEDICAL JOURNAL, 2011, 卷号: 124 -   |  收藏  |  浏览/下载：31/0  |  提交时间：2020/10/26 POSITRON-EMISSION-TOMOGRAPHY  TUMOR RESPONSE  TYROSINE KINASE  GEFITINIB  EGFR  PET  MUTATIONS  ERLOTINIB  DNA  C-11-PD153035  lung cancer  epidermal growth factor receptors  molecular imaging   Recursive Partitioning Analysis Classification and Graded Prognostic Assessment for Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Retrospective Cohort Study 期刊论文  OAI收割 CHINESE JOURNAL OF CANCER RESEARCH, 2011, 卷号: 23 -   |  收藏  |  浏览/下载：9/0  |  提交时间：2020/10/26 CLINICAL-PRACTICE GUIDELINE  SURGICAL-TREATMENT  RADIATION-THERAPY  ANALYSIS RPA  STEREOTACTIC RADIOSURGERY  MANAGEMENT  CHEMOTHERAPY  RADIOTHERAPY  ERLOTINIB  SURVIVAL  Non-small cell lung cancer (NSCLC)  Brain metastasis  Prognosis  Recursive partitioning analysis  Graded prognostic assessment